Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival

Xiaoyun Liao; Paul Lochhead; Reiko Nishihara; Teppei Morikawa; Aya Kuchiba; Mai Yamauchi; Yu Imamura; Zhi Rong Qian; Yoshifumi Baba; Kaori Shima; Ruifang Sun; Katsuhiko Nosho; Jeffrey A. Meyerhardt; Edward Giovannucci; Charles S. Fuchs; Andrew T. Chan; Shuji Ogino

doi:10.1056/NEJMoa1207756

Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival

Xiaoyun Liao, Paul Lochhead, Reiko Nishihara, Teppei Morikawa, Aya Kuchiba, Mai Yamauchi, Yu Imamura, Zhi Rong Qian, Yoshifumi Baba, Kaori Shima, Ruifang Sun, Katsuhiko Nosho, Jeffrey A. Meyerhardt, Edward Giovannucci, Charles S. Fuchs, Andrew T. Chan, Shuji Ogino

Applied Medicine

Research output: Contribution to journal › Article › peer-review

693 Citations (Scopus)

Abstract

Regular use of aspirin after a diagnosis of colon cancer has been associated with a superior clinical outcome. Experimental evidence suggests that inhibition of prostaglandin-endoperoxide synthase 2 (PTGS2) (also known as cyclooxygenase-2) by aspirin down-regulates phosphatidylinositol 3-kinase (PI3K) signaling activity. We hypothesized that the effect of aspirin on survival and prognosis in patients with cancers characterized by mutated PIK3CA (the phosphatidylinositol-4,5-bisphosphonate 3-kinase, catalytic subunit alpha polypeptide gene) might differ from the effect among those with wild-type PIK3CA cancers.

Original language	English
Pages (from-to)	1596-1606
Number of pages	11
Journal	The New England Journal of Medicine
Volume	367
Issue number	17
DOIs	https://doi.org/10.1056/NEJMoa1207756
Publication status	Published - 25 Oct 2012

Bibliographical note

PMID: 23094721 [PubMed - indexed for MEDLINE] PMCID: PMC3532946 Free PMC Article

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1056/NEJMoa1207756

Cite this

Liao, X., Lochhead, P., Nishihara, R., Morikawa, T., Kuchiba, A., Yamauchi, M., Imamura, Y., Qian, Z. R., Baba, Y., Shima, K., Sun, R., Nosho, K., Meyerhardt, J. A., Giovannucci, E., Fuchs, C. S., Chan, A. T., & Ogino, S. (2012). Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. The New England Journal of Medicine, 367(17), 1596-1606. https://doi.org/10.1056/NEJMoa1207756

Liao, X, Lochhead, P, Nishihara, R, Morikawa, T, Kuchiba, A, Yamauchi, M, Imamura, Y, Qian, ZR, Baba, Y, Shima, K, Sun, R, Nosho, K, Meyerhardt, JA, Giovannucci, E, Fuchs, CS, Chan, AT & Ogino, S 2012, 'Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival', The New England Journal of Medicine, vol. 367, no. 17, pp. 1596-1606. https://doi.org/10.1056/NEJMoa1207756

@article{4b6c1835aca04e999de32e5b57dae79b,

title = "Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival",

abstract = "Regular use of aspirin after a diagnosis of colon cancer has been associated with a superior clinical outcome. Experimental evidence suggests that inhibition of prostaglandin-endoperoxide synthase 2 (PTGS2) (also known as cyclooxygenase-2) by aspirin down-regulates phosphatidylinositol 3-kinase (PI3K) signaling activity. We hypothesized that the effect of aspirin on survival and prognosis in patients with cancers characterized by mutated PIK3CA (the phosphatidylinositol-4,5-bisphosphonate 3-kinase, catalytic subunit alpha polypeptide gene) might differ from the effect among those with wild-type PIK3CA cancers.",

author = "Xiaoyun Liao and Paul Lochhead and Reiko Nishihara and Teppei Morikawa and Aya Kuchiba and Mai Yamauchi and Yu Imamura and Qian, {Zhi Rong} and Yoshifumi Baba and Kaori Shima and Ruifang Sun and Katsuhiko Nosho and Meyerhardt, {Jeffrey A.} and Edward Giovannucci and Fuchs, {Charles S.} and Chan, {Andrew T.} and Shuji Ogino",

note = "PMID: 23094721 [PubMed - indexed for MEDLINE] PMCID: PMC3532946 Free PMC Article",

year = "2012",

month = oct,

day = "25",

doi = "10.1056/NEJMoa1207756",

language = "English",

volume = "367",

pages = "1596--1606",

journal = "The New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachussetts Medical Society",

number = "17",

}

TY - JOUR

T1 - Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival

AU - Liao, Xiaoyun

AU - Lochhead, Paul

AU - Nishihara, Reiko

AU - Morikawa, Teppei

AU - Kuchiba, Aya

AU - Yamauchi, Mai

AU - Imamura, Yu

AU - Qian, Zhi Rong

AU - Baba, Yoshifumi

AU - Shima, Kaori

AU - Sun, Ruifang

AU - Nosho, Katsuhiko

AU - Meyerhardt, Jeffrey A.

AU - Giovannucci, Edward

AU - Fuchs, Charles S.

AU - Chan, Andrew T.

AU - Ogino, Shuji

N1 - PMID: 23094721 [PubMed - indexed for MEDLINE] PMCID: PMC3532946 Free PMC Article

PY - 2012/10/25

Y1 - 2012/10/25

N2 - Regular use of aspirin after a diagnosis of colon cancer has been associated with a superior clinical outcome. Experimental evidence suggests that inhibition of prostaglandin-endoperoxide synthase 2 (PTGS2) (also known as cyclooxygenase-2) by aspirin down-regulates phosphatidylinositol 3-kinase (PI3K) signaling activity. We hypothesized that the effect of aspirin on survival and prognosis in patients with cancers characterized by mutated PIK3CA (the phosphatidylinositol-4,5-bisphosphonate 3-kinase, catalytic subunit alpha polypeptide gene) might differ from the effect among those with wild-type PIK3CA cancers.

AB - Regular use of aspirin after a diagnosis of colon cancer has been associated with a superior clinical outcome. Experimental evidence suggests that inhibition of prostaglandin-endoperoxide synthase 2 (PTGS2) (also known as cyclooxygenase-2) by aspirin down-regulates phosphatidylinositol 3-kinase (PI3K) signaling activity. We hypothesized that the effect of aspirin on survival and prognosis in patients with cancers characterized by mutated PIK3CA (the phosphatidylinositol-4,5-bisphosphonate 3-kinase, catalytic subunit alpha polypeptide gene) might differ from the effect among those with wild-type PIK3CA cancers.

U2 - 10.1056/NEJMoa1207756

DO - 10.1056/NEJMoa1207756

M3 - Article

C2 - 23094721

SN - 0028-4793

VL - 367

SP - 1596

EP - 1606

JO - The New England Journal of Medicine

JF - The New England Journal of Medicine

IS - 17

ER -

Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival

Abstract

Bibliographical note

UN SDGs

Access to Document

Fingerprint

Cite this